iRadimed Corporation $IRMD Shares Sold by Rice Hall James & Associates LLC

Posted by Brian Himes on Jun 17th, 2026

Rice Hall James & Associates LLC trimmed its holdings in iRadimed Corporation (NASDAQ:IRMD – Free Report) by 15.1% in the fourth quarter, Holdings Channel.com reports. The fund owned 36,993 shares of the medical equipment provider’s stock after selling 6,600 shares during the period. Rice Hall James & Associates LLC’s holdings in iRadimed were worth $3,599,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Barclays PLC lifted its holdings in iRadimed by 7.8% in the 4th quarter. Barclays PLC now owns 25,849 shares of the medical equipment provider’s stock valued at $2,515,000 after acquiring an additional 1,862 shares during the last quarter. Bridge City Capital LLC lifted its holdings in iRadimed by 19.4% in the 4th quarter. Bridge City Capital LLC now owns 70,854 shares of the medical equipment provider’s stock valued at $6,893,000 after acquiring an additional 11,509 shares during the last quarter. State Street Corp lifted its holdings in iRadimed by 3.1% in the 4th quarter. State Street Corp now owns 192,952 shares of the medical equipment provider’s stock valued at $18,770,000 after acquiring an additional 5,713 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in iRadimed by 21.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,875 shares of the medical equipment provider’s stock valued at $1,447,000 after acquiring an additional 2,595 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in iRadimed by 70.5% in the 4th quarter. Wells Fargo & Company MN now owns 9,696 shares of the medical equipment provider’s stock valued at $943,000 after acquiring an additional 4,009 shares during the last quarter. 92.34% of the stock is owned by institutional investors and hedge funds.

iRadimed Trading Up 1.2%

IRMD stock opened at $91.84 on Wednesday. The firm has a 50-day moving average of $90.69 and a two-hundred day moving average of $95.90. The firm has a market capitalization of $1.17 billion, a PE ratio of 50.19 and a beta of 0.91. iRadimed Corporation has a one year low of $55.11 and a one year high of $107.90.

iRadimed (NASDAQ:IRMD – Get Free Report) last posted its quarterly earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $0.03. The business had revenue of $21.98 million during the quarter, compared to analyst estimates of $21.32 million. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. On average, equities research analysts anticipate that iRadimed Corporation will post 1.52 earnings per share for the current year.

iRadimed Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, May 29th. Stockholders of record on Friday, May 15th were given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend was Friday, May 15th. iRadimed’s dividend payout ratio is 43.72%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Freedom Capital raised shares of iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. Weiss Ratings lowered shares of iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday, May 20th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, iRadimed has an average rating of “Buy” and a consensus target price of $120.00.

Read Our Latest Stock Analysis on iRadimed

Insider Activity

In other news, CEO Roger E. Susi sold 2,500 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.60, for a total value of $226,500.00. Following the completion of the sale, the chief executive officer directly owned 2,162,500 shares of the company’s stock, valued at $195,922,500. This represents a 0.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 55,000 shares of company stock valued at $5,031,903 over the last ninety days. 34.60% of the stock is owned by corporate insiders.

iRadimed Company Profile

(Free Report)

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.